AIM ImmunoTech (AIM) Change in Accured Expenses (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Change in Accured Expenses data on file, last reported at $31000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 50.0% year-over-year to $31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $385000.0 (up 164.6% YoY) and the FY2025 annual result came in at $416000.0, up 134.72% from the prior year.
• Change in Accured Expenses fell to $31000.0 in Q1 2026, from $162000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.3 million in Q3 2022 to a low of -$961000.0 in Q4 2022.
• A 5-year average of $46882.4 and a median of $31000.0 in 2026 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 11600.0% in 2022, down 1364.47% in 2022.
• Tracing AIM's Change in Accured Expenses over 5 years: stood at -$961000.0 in 2022, then surged by 127.58% to $265000.0 in 2023, then slumped by 250.57% to -$399000.0 in 2024, then surged by 140.6% to $162000.0 in 2025, then sank by 80.86% to $31000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $31000.0 (Q1 2026), $162000.0 (Q4 2025), and $287000.0 (Q3 2025), per Business Quant data.